Clinical Trial Update: Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab

View source ↗

Summary

A registry study assessing compliance among Colombian rheumatoid arthritis patients treated with golimumab has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Simponi (golimumab)

Snippet

Sponsor: Janssen-Cilag, S.A. | Conditions: Rheumatoid Arthritis | Status: TERMINATED